Immunotherapeutic options on the horizon in breast cancer treatment

Rooijen, Johan M. van; Stutvoet, Thijs S.; Schröder, Carolien P.; Vries, Elisabeth G.E. de

doi:10.1016/j.pharmthera.2015.09.003

Cited by 17 publications

(14 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to the absence of effective targeted therapy, chemotherapy is the only recommended systemic treatment for TNBCs at present stage [4]. However, various therapeutic strategies have been explored, among which immunotherapy may have potential benefits to treat TNBCs [5, 6]. Therefore, several studies have been carried out to evaluate the predictive and prognostic values of tumor-infiltrating lymphocytes (TILs) in TNBCs, which have indicated that high levels of TILs may be associated with a better clinical outcome and a better response to chemotherapy in TNBCs [7–9].…”

Section: Introductionmentioning

confidence: 99%

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

et al. 2018

View full text Add to dashboard Cite

BackgroundTriple-negative breast cancers (TNBCs) are a group of heterogeneous diseases with various morphology, prognosis, and treatment response. Therefore, it is important to identify valuable biomarkers to predict the therapeutic response and prognosis for TNBCs. Tumor-infiltrating lymphocytes (TILs) may have predictive value to pathological complete response (pCR) in neoadjuvant treated TNBCs. However, absence of standardized methodologies for TILs measurement has limited its evaluation and application in practice. In 2014, the International TILs Working Group formulated the recommendations of pathologic evaluation for TILs in breast cancers.MethodsTo evaluate the predictive value of TILs scored by methods recommended by International TILs Working Group 2014, we performed a retrospective study of TILs in 166 core needle biopsy specimens of primary invasive TNBCs with neoadjuvant chemotherapy (NAC) in a Chinese population. Intratumoral TILs (iTILs) and stromal TILs (sTILs) were scored respectively. The associations between TILs and pCR were analyzed.ResultsBoth sTILs (p = 0.0001) and iTILs (P = 0.001) were associated with pCR in univariate logistic regression analysis. Multivariate logistic regression analysis indicated that both sTILs (P = 0.006) and iTILs (P = 0.04) were independent predictors for pCR. Receiver operating characteristics (ROC) curve analysis was used to identify the optimal thresholds of TILs. TNBCs with more than 20% sTILs (P = 0.001) or with more than 10% iTILs (P = 0.003) were associated with higher pCR rates in univariate analysis. Multivariate analysis showed that a 20% threshold of sTILs (P = 0.005) was an independent predictive factor for pCR.ConclusionsOur study indicated that TILs scored by recommendations of International TILs Working Group 2014 in pre-NAC core needle biopsy specimens was significantly correlated with pCR in TNBCs, higher TILs scores predicting higher pCR rate. Both sTILs and iTILs were independent predictors for pCR in TNBCs. A 20% threshold for sTILs may be feasible to predict pCR to NAC in TNBCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Thus aiming a single gene product or cell signaling pathway is unlikely to prevent or treat breast cancer. The current therapeutic options for breast cancer (surgical resection, radiation, and chemotherapeutic agents) [7–12] are not only costly but also modify many normal gene functions. Present-day strategy of breast cancer therapy and prevention is either combination of a number of drugs or a drug that modulates multiple targets.…”

Section: Introductionmentioning

confidence: 99%

Curcumin: the spicy modulator of breast carcinogenesis

Banik

Parasuraman

Adhikary

et al. 2017

J Exp Clin Cancer Res

126

View full text Add to dashboard Cite

Worldwide breast cancer is the most common cancer in women. For many years clinicians and the researchers are examining and exploring various therapeutic modalities for breast cancer. Yet the disease has remained unconquered and the quest for cure is still going on. Present-day strategy of breast cancer therapy and prevention is either combination of a number of drugs or a drug that modulates multiple targets. In this regard natural products are now becoming significant options. Curcumin exemplifies a promising natural anticancer agent for this purpose. This review primarily underscores the modulatory effect of curcumin on the cancer hallmarks. The focus is its anticancer effect in the complex pathways of breast carcinogenesis. Curcumin modulates breast carcinogenesis through its effect on cell cycle and proliferation, apoptosis, senescence, cancer spread and angiogenesis. Largely the NFkB, PI3K/Akt/mTOR, MAPK and JAK/STAT are the key signaling pathways involved. The review also highlights the curcumin mediated modulation of tumor microenvironment, cancer immunity, breast cancer stem cells and cancer related miRNAs. Using curcumin as a therapeutic and preventive agent in breast cancer is perplexed by its diverse biological activity, much of which remains inexplicable. The information reviewed here should point toward potential scope of future curcumin research in breast cancer.

show abstract

“…This has been clearly shown for TNBC and HER-2 C BC wherein a strong association between higher lymphocytic infiltrations predicts a better outcome. 26,27 Histological studies have shown that co-localization of immune cells with cancer cells is significantly associated with a survival benefit for all BC subtypes. 28 It is not yet clear which immune cell types are useful as prognostic markers, and importantly whether they differ between BC subtypes.…”

Section: Immune Cells As Prognostic and Predictive Markers Of Responsmentioning

confidence: 99%

A review of the importance of immune responses in luminal B breast cancer

et al. 2017

View full text Add to dashboard Cite

Historically, the immune environment was not considered an important target for breast cancer treatment. However, the association of lymphocytic infiltrates in triple negative and HER-2 over-amplified breast cancer subtypes with better outcomes, has provoked interest in evaluating the role of the immune system in the luminal B subtype that accounts for 39% of breast cancers and has a poor patient prognosis. It is unknown which immunosuppressive cell types or molecules (e.g., checkpoint molecules) are relevant, or where measurement is most informative. We hypothesize that a profound immunosuppressive tumor and/or lymph node milieu is prognostic and impacts on responses to therapies.

show abstract

Immunotherapeutic options on the horizon in breast cancer treatment

Cited by 17 publications

References 126 publications

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Curcumin: the spicy modulator of breast carcinogenesis

A review of the importance of immune responses in luminal B breast cancer

Contact Info

Product

Resources

About